Bristol-Myers Squibb has announced further results of its ongoing clinical research into the treatment of the hepatitis C virus (HCV).
The firm had already revealed it found that combining the potent antiviral activity of daclatasvir with a nucleotide analogue polymerase inhibitor has the potential to address a once-daily, pan-genotypic oral combination regimen.
Now, Phase IIb Emerge trials in 118 treatment-naive patients chronically infected with genotype 2 or 3 HCV have been revealed.
Rates of serious adverse events and adverse events were described as being similar across treatment arms, with fewer flu-like and musculoskeletal symptoms in the Lambda/RBV.
Stefan Zeuzem MD, chief of the department of medicine and professor of medicine at the Goethe University Hospital in Frankfurt in Germany, explained the implications of these findings.
"There is a significant unmet medical need for antiviral therapies that can benefit more hepatitis C patients with a goal of decreasing treatment-related adverse events and potentially reducing treatment duration," he commented.